Radius Health (RDUS) Upgraded at Zacks Investment Research
Radius Health (NASDAQ:RDUS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday.
According to Zacks, “Radius received a major boost with the approval of Tymlos for the treatment of postmenopausal women with high risk osteoporosis for fracture. Although the osteoporosis market has a great potential as approximately 1.4 million postmenopausal women in the United States experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's Forteo and Amgen’s Prolia. Further, the company suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues to its MAA for Eladynos in Europe. The CHMP will issue a third Day-180 List of Outstanding Issues in its regulatory review of abaloparatide-SC. While Radius' efforts in developing its pipeline are encouraging, we note that most of its candidates are in their early or mid stages of development. The company’ shares have underperformed the industry in the last twelve months.”
A number of other research firms have also commented on RDUS. Maxim Group reaffirmed a “positive” rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Goldman Sachs Group reiterated a “neutral” rating and issued a $45.00 target price on shares of Radius Health in a research report on Friday, October 6th. BidaskClub upgraded shares of Radius Health from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 27th. Cantor Fitzgerald reiterated a “buy” rating and issued a $58.00 target price on shares of Radius Health in a research report on Friday, November 3rd. Finally, Jefferies Group cut their target price on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a research report on Friday, November 3rd. Two analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $48.00.
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The company had revenue of $13.50 million for the quarter, compared to analysts’ expectations of $6.90 million. During the same period last year, the company earned ($1.07) earnings per share. equities analysts expect that Radius Health will post -5.57 earnings per share for the current year.
In other Radius Health news, VP Brent Hatzis-Schoch purchased 1,778 shares of the business’s stock in a transaction dated Friday, November 10th. The shares were acquired at an average price of $28.09 per share, for a total transaction of $49,944.02. Following the acquisition, the vice president now owns 2,278 shares of the company’s stock, valued at $63,989.02. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech purchased 50,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were acquired at an average price of $26.25 per share, for a total transaction of $1,312,500.00. Following the acquisition, the insider now directly owns 5,698,799 shares in the company, valued at approximately $149,593,473.75. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 158,578 shares of company stock valued at $4,659,916. Insiders own 15.00% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC bought a new position in shares of Radius Health during the 3rd quarter valued at $110,000. Sei Investments Co. raised its holdings in shares of Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 690 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Radius Health by 19.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 541 shares in the last quarter. Advisor Group Inc. raised its holdings in shares of Radius Health by 267.2% during the 2nd quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,888 shares in the last quarter. Finally, Amalgamated Bank bought a new position in shares of Radius Health during the 2nd quarter valued at $211,000.
WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/08/radius-health-rdus-upgraded-at-zacks-investment-research.html.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.